Optimal delay for hepatobiliary phase MRI with gadobenate dimeglumine

Optimal delay for hepatobiliary phase MRI with gadobenate dimeglumine - Delay time gadobenate dimeglumine

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON44618

Enrollment

Registered

2016-02-09

Start date

2016-02-15

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular adenomas liver lesion

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - 18 years or older - capacity to read and interpret informed consent - clinical indication for MRI with gadobenate dimeglumine, including delayed phase imaging after one hour

Exclusion criteria

Exclusion criteria: - contraindication for MRI - contraindication for gadobenate dimeglumine

Design outcomes

Primary

Measure	Time frame
- Quantitative assessment: only lesions larger than 1 cm will be included (measurements in smaller lesions are less accurate). A ROI will be placed in each lesions and in the neighboring liver. Measurement will be performed at every time point including the late hepatobiliary phase. - Qualitative assessment: all visible lesions will be included. Two readers will independently choose the turning time point where a lesion becomes hypointense to the surrounding liver. A consensus reading will be performed and interreader agreement will be evaluated. - The percentage of lesions that become hypointense to the liver measured every 2.5 minutes during 45 minutes will be extrapolated with 95 % confidence intervals	—

Measure

Time frame

- Quantitative assessment: only lesions larger than 1 cm will be included (measurements in smaller lesions are less accurate). A ROI will be placed in each lesions and in the neighboring liver. Measurement will be performed at every time point including the late hepatobiliary phase. - Qualitative assessment: all visible lesions will be included. Two readers will independently choose the turning time point where a lesion becomes hypointense to the surrounding liver. A consensus reading will be performed and interreader agreement will be evaluated. - The percentage of lesions that become hypointense to the liver measured every 2.5 minutes during 45 minutes will be extrapolated with 95 % confidence intervals

—

Secondary

Measure	Time frame
- The effect of changing flip angle on the T1-weighting will be studied	—

Countries

Netherlands

Outcome results